Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nenocorilant + Nivolumab in Advanced Solid Malignancies
NCT07276373Phase 2Recruiting
- Sponsor
- Corcept Therapeutics
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
A Phase 2 trial of CORT125236 in Solid malignancy, sponsored by Corcept Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
CORT125236
03
Conditions
Solid malignancy
Beyond the preview
Go deeper on NCT07276373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276373.